{"id":"W4408567665","doi":"10.1053/j.gastro.2025.02.033","title":"Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI Study","year":2025,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Genentech; Mitsubishi Tanabe Pharma Corporation; Celltrion; Kissei; Mylan; Boston Scientific Corporation; Teva Pharmaceutical Industries; EA Pharma Co., Ltd.; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; Kyorin Pharmaceutical; Pfizer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Johnson and Johnson; Takeda Pharmaceutical Company","keywords":"Crohn's disease; Medicine; Disease; Phase (matter); Internal medicine; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001355119,0.0001474209,0.0001758583,0.00004252183,0.00006724673,0.00001250046,0.0001092764,0.00004804535,0.000001429871],"category_scores_gemma":[0.0001567826,0.0001117622,0.00001753344,0.00005380261,0.0001530539,0.000005756989,0.0001309246,0.00009549072,4.205616e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001873832,"about_ca_system_score_gemma":0.00004831435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008845154,"about_ca_topic_score_gemma":0.001859899,"domain_scores_codex":[0.9987392,0.000229849,0.0002613455,0.0004263186,0.00007018016,0.0002731255],"domain_scores_gemma":[0.9993927,0.000031924,0.0001037241,0.0003073628,0.00006134454,0.0001029442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7964938,0.001155431,0.1903549,0.00002024133,0.0003514555,0.0007872599,0.001495588,0.001215571,0.005689621,0.00002054725,0.0001932774,0.002222274],"study_design_scores_gemma":[0.009743723,0.001088501,0.9880407,0.00003265098,0.00007283098,0.00001026092,0.0004208809,0.00007709714,0.0003744759,0.00003121666,0.00004167107,0.00006592985],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981734,0.00002861958,0.0001973971,0.0004504857,0.00004686494,0.0007257681,0.0003576949,0.000005576167,0.00001425795],"genre_scores_gemma":[0.9994305,0.00001996608,0.00004868931,0.0003214936,0.00002195314,0.00005565909,0.0000663925,0.000009601084,0.00002572449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7976859,"threshold_uncertainty_score":0.455753,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01122814000109858,"score_gpt":0.2668164710377605,"score_spread":0.255588331036662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}